Document:

Converted by EDGARwiz

•

Bi INVENT

Jeff Morhet, President and CEO InNexus Biotechnology, Inc

13208 East Shea Blvd, Suite 200 The Mayo Clinic MCCRB Building Scottsdale, AZ 85259

USA

September 27, 2006

R&D and License Agreement Dear Mr Morhet:

Please find enclosed the two original R&D and License Agreements between InNexus and Biolnvent for your signature. After signature return one copy to me at address:

Biolnvent International AB Marie Serwe

Solvegatan 41

SE-223 70 Lund

Sweden

Sincerely,

Marie Serwe Executive Assistant

Encls

Biolnvent International AB (publ)

Solvegatan 41

Phone: +46 46 286 85 50

5E556537726301

556537-7263

SE-223 70 LUND, Sweden

Fax:

+46 46 211 08 06

Styrelsens sate: Lund e-mail: infoCbioinvent.com

www.bioinvent.com

R&D and LICENSE AGREEMENT

Effective on the date indicated below, InNexus Biotechnology, Inc., 200 Granville Street, Suite 2760, Vancouver, BC, Canada V6C 1S4 with principle management being based at 13208 East Shea Boulevard, Suite 200, Scottsdale, AZ 85259 (hereinafter "INNEXUS") and BioInvent International AB (publ.), a corporation, located at Solvegatan 41, SE-223 70 Lund, Sweden (hereinafter "Biolnvent"] and collectively the 'Parties", agree to enter into a Research & Development and License agreement where Biolnvent will provide to INNEXUS with certain BIOINVENT OWNED MATERIALS and CONFIDENTIAL INFORMATION (as defined herein) to effect potency enhancement of such materials where Biolnvent upon successful completion of the R&D WORK PLAN will subsequently have the right to license from InNexus the enhanced potency Materials subject to the following terms and conditions:

1. DEFINITIONS & MEANINGS:

BIOINVENT ANTIBODY: that Antibody as identified as being a fully human anti HLA-DR monoclonal antibody, or an antibody to any substituted TARGET, as supplied in the WORK PLAN by Biolnvent to INNEXUS, under this Agreement excluding the INNEXUS MATERIALS.

BIOINVENT OWNED MATERIALS: materials provided to INNEXUS by BioInvent under this Agreement, including but not limited to those provided under the WORK PLAN. Except as outlined under the terms and condition defined herein Biolnvent can not commercialize, sell, or transfer to any third party material including any InNexus Materials, or material produced using InNexus INTELLECTUAL PROPERTY

BIOINVENT EQUIVALENT ANTIBODY shall mean a BIOINVENT ANTIBODY; recombinantly produced using certain cell lines, which have been genetically modified to produce an antibody which is equivalent to the original SUPER BIOINVENT ANTIBODY which was produced via chemical conjugation methods. For the sake of clarity, the BIOINVENT EQUIVALENT ANTIBODY must show equivalent binding properties, affinity, and efficacy as defined in the R&D WORK PLAN, and toxicity profile in preclinical tests as the SUPER BIOINVENT ANTIBODY that was produced via chemical conjugation methods. The BIOINVENT EQUIVALENT ANTIBODY will be developed by INNEXUS on its own expense using reasonable commercial efforts. If INNEXUS fails to develop the BIOINVENT EQUIVALENT ANTIBODY within the time frames defined in the WORK PLAN, BIOINVENT will have the right to develop a BIOINVENT EQUIVALENT ANTIBODY to the TARGET on its own expense, under InNexus I.P. rights and know -how.

CONFIDENTIAL INFORMATION: confidential information of each party.

EXCLUSIVITY: shall mean the definition as further defined in section 7b) herein; which will also be included and or expanded upon in any future license agreement for the BioInvent Antibody defined herein; between the Parties.

INNEXUS OWNED MATERIALS: materials provided by INNEXUS to Biolnvent under this Agreement, including but not limited to those provided under the WORK PLAN. For the sake of clarity, INNEXUS can not claim any ownership in BioInvent Antibody or BioInvent Owned Material. InNexus can not commercialize, sell, or transfer to any third party material including any BioInvent Materials, or material produced using BioInvent INTELLECTUAL PROPERTY.

INTELLECTUAL PROPERTY: Subject to Article 4 and 6 below and for the purposes of this agreement and subsequent license arising from this agreement only - there will be no joint intellectual property created as a result of or used pursuant to undertaking the tasks and responsibilities set forth in the R&D WORK PLAN. All Intellectual Property rights which existed prior

to the entering of this agreement and as may exist thereafter the execution of this agreement by each of the Parties remain the property of the individual Party.

The Super Antibody and the BIOINVENT EQUIVALENT ANTIBODY versions of the Biolnvent Antibody defined in the R&D WORK PLAN herein; in its finished form and as supplied to BioInvent from InNexus, will upon execution of the license according to clause 7 below, become the sole property of Biolnvent, and will thereafter not be part of INNEXUS OWNED MATERIALS.

The Super BioInvent Antibody which is proposed to be created under the R&D WORK PLAN herein will become the property of Biolnvent and Biolnvent will be responsible for any patent filings herein, and even though the Super Biolnvent Antibody contains Joint Materials, any such filings by Biolnvent will not make any claims in any current or subsequent form thereof to any InNexus material, InNexus Intellectual Property rights or technology patents or continuations thereof.

JOINT MATERIALS: collectively the INNEXUS MATERIALS and Biolnvent MATERIALS.

PROVIDER: a party that provides CONFIDENTIAL INFORMATION and/or MATERIALS to the other party under this agreement.

R&D WORK PLAN: The R&D WORK PLAN is attached as Exhibit A. It is agreed such plan may be modified from time to time upon mutual agreement of the Parties; to effect a superior and successful completion of said plan.

RECIPIENT: a party that receives CONFIDENTIAL INFORMATION and/or MATERIALS from the other party under this agreement.

SCIENTIST: the individual designated by each party to direct its activities under the R&D WORK PLAN.

SUPER BIOINVENT ANTIBODY: shall mean that specific Biolnvent Antibody defined in the WORK PLAN herein which INNEXUS has chemically conjugation and or otherwise modified through the application of its Super Antibody Technology.

TARGET: The DNA, all post-transcriptional material encoded by such DNA, including all naturally occurring or disease-associated truncations, mutations, variants, fragments, and post-transcriptional modifications thereof (including splice variants) and including all material encoded by such post-transcriptional material, including proteins. For the avoidance of doubt, this definition of TARGET shall include all epitopes on the TARGET and shall exclude antibodies. The identity of the TARGET (including Gene Bank number) is attached as Exhibit C.

WORK PLAN FEE: Subject to Article 12 below Biolnvent shall pay to InNexus a non refundable non creditable fee at the initiation of the R&D WORK PLAN.

2.

PURPOSE: The assessment of BioInvent Antibodies as SUPER BioInvent ANTIBODIES using the assay systems as defined in the R&D WORK PLAN to demonstrate an increase or enhancement in potency or effect of the SUPER BIOINVENT ANTIBODY for use against the TARGET.

3.

PUBLICATION AND DISCLOSURE: Each party shall be given free access and use such generated data upon completion of the WORK PLAN. Any disclosure of the data to a third party by INNEXUS shall not include any information that allows or is sufficient for the identification of the BioInvent ANTIBODIES, Super BioInvent Antibodies to the TARGET, or the TARGET unless agreed to by Biolnvent.

2.

4. RESERVATION OF TITLE: Each PROVIDER retains ownership of its OWN MATERIALS and CONFIDENTIAL INFORMATION it transfers to a RECIPIENT as well as all aspects of its MATERIALS and CONFIDENTIAL INFORMATION incorporated into the SUPERANTIBODIES. Each RECIPIENT acknowledges that its PROVIDER'S MATERIALS and CONFIDENTIAL INFORMATION may be the subject of a patent, trademark, or any other proprietary rights of its PROVIDER.

5. SOLE PURPOSE: Each RECIPIENT agrees that its PROVIDER'S MATERIALS are to be used only at RECIPIENT'S facility and only in RECIPIENT'S laboratory under the direction of RECIPIENT'S SCIENTIST or others working under direct supervision of such for the sole purpose as given in article two (2) above. A PROVIDER'S MATERIALS will not be transferred to any third party by a RECIPIENT without the prior written consent of the PROVIDER.

6. OWNERSHIP OF INTELLECTUAL PROPERTY: The parties shall each own INTELLECTUAL PROPERTY as follows:

(a)

INNEXUS shall own existing INTELLECTUAL PROPERTY that generally claims, embodies and/or constitutes INNEXUS MATERIALS, methods of making INNEXUS MATERIALS, and methods of using INNEXUS MATERIALS.

(b)

BloInvent shall own existing INTELLECTUAL PROPERTY that generally and specifically claims, embodies and/or constitutes the BloInvent MATERIALS, methods of making the BloInvent MATERIALS, and methods of using the Biolnvent MATERIALS.

(c)

Neither party shall make a patent claim on each others technologies, know how, or on any materials related to any recombinant technology or other Super Antibody technology, BioInvent technology; which may be contained within the Super BioInvent Antibody unless agreed to by the other party.

7. LICENSE OPTION, TERMS and CONDITIONS: If further development of the SUPER ANTIBODY or a BIOINVENT EQUIVALENT ANTIBODY is deemed commercially viable by BIOINVENT, and at latest upon successful completion of the WORK PLAN and for sixty (60) days there after (the Option Period); unless mutually agreed upon to extend such period for a further thirty (30) days the Parties will:

a)

Immediately enter into good faith negotiations to fully define the full and complete terms of an exclusive world wide commercialization license, to use, import, sell sub-license or otherwise commercialize a SUPER ANTIBODY or a BIOINVENT EQUIVALENT ANTIBODY version of the BioInvent antibody as identified in the WORK PLAN. These license terms (the "Terms") in general will follow a format of fee for service where these fees will be spread over certain milestones; payable at mutually agreed upon times and or events. Manufacturing fees and exclusivity fees will also apply as defined below. The table of fees for service license, manufacturing and exclusivity fees are attached as Exhibit B herein.

b)

For purposes of this agreement the grant of "exclusivity" shall be specific for the one antigen TARGET as further defined in Exhibit C, and for application and use as a cancer therapeutic. For the sake of clarity, BioInvent will have the right to develop the Super Antibody and the BIOINVENT EQUIVALENT ANTIBODY to any other indication on a non-exclusive basis. If the development of a SUPER BIOINVENT ANTIBODY against the TARGET is unsuccessful, as defined by the WORK PLAN, Biolnvent will have the right to substitute the original TARGET with another TARGET. For the sake of clarity, InNexus will have the right to decline the development of any such SUPER BIOINVENT ANTIBODY against any such substituted TARGET for competitive reasons.

c)

Work Plan and Subsequent Fees - During the R&D WORK PLAN InNexus will conjugate the cross linking peptide sequence to the BioInvent Antibody and will conjugate the initial 10 mg amount of conjugated antibody to Biolnvent for a fee of USD$10,500. For any subsequent research

a)

studies InNexus will conjugate the BioInvent Antibody with the same research grade peptide and deliver to Biolnvent in 5 rng batch lots at the agreed upon price of $2,500.

d) In the event a RECOMBINANT EQUIVALENT antibody is not available for any subsequent pilot, preclinical or scale -up periods studies; InNexus will supply for BioInvent any additionally required conjugated Super BioInvent Antibody using pharmaceutical grade peptide conjugate. To be clear the peptide conjugate shall be of cGMP standard and as such will be provided at the prevailing rates reflecting this standard of quality to effect transfer of title. The Biolnvent Antibody for such conjugation/manufacture by InNexus will be supplied at no cost to InNexus by BioInvent.

d)

Grant of primary and secondary manufacturer status - Upon delivery by InNexus of a RECOMBINANT EQUIVALENT Antibody, InNexus will supply those materials such as cell lines and other know how necessary for the manufacturing know how of the RECOMBINANT EQUIVALENT Antibody to Biolnvent. BioInvent is granted; subject to the fees in Exhibit B the status of primary manufacturer. In the event volume requirements of the final product exceed BioInvent's manufacturing capabilities, InNexus is granted the right to act as a secondary manufacturer of said product.

e)

In recognition of and because of various partnerships to which InNexus is a member, InNexus may be able to reduce royalty stacking amounts for Biolnvent. In the event where InNexus demonstrates such to Biolnvent and BioInvent agrees such royalty stack for BioInvent has been reduced; InNexus may add a royalty back-in number equal to 50% of the royalty stack amount so saved; such that if for example InNexus can reduce BioInvent's royalty stack by 2%, 1% will be returned to InNexus and if 4% then 2% etc.

8.

NO WARRANTY: Any MATERIALS delivered or disclosed pursuant to the MTA Agreement are understood to be experimental in nature and may have hazardous properties. Each PROVIDER

MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIALS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

9.

HOLD HARMLESS: Except to the extent prohibited by law, each party assumes all liability for damages, which may arise from its use, storage or disposal of the MATERIALS. No PROVIDER will

be liable to any RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against

the RECIPIENT by any other party, due to or arising from the use of the MATERIALS by the RECIPIENT.

10.

COMPLIANCE WITH FEDERAL REGULATIONS: Each RECIPIENT agrees to use MATERIALS received from its PROVIDER in compliance with all applicable state, provincial and federal statutes

and regulations, including Public Health Services and or National Institutes of Health regulations

and guidelines. In particular, RECIPIENT will not use the MATERIALS in human subjects.

11.

TERMINATION TERMS OF AGREEMENT: This Agreement will expire or terminate on the earliest of the following dates:

a)

Upon mutual agreement the WORK PLAN results do not show enhanced potency of the SUPER BIOINVENT ANTIBODY then this agreement may be immediately terminated by either of the Parties. However the Parties may entertain to continue, or modify such WORK PLAN to determine a successful outcome, which in such case the articles of this agreement will be extended to cover the period of the new WORK PLAN and any license option period.

b)

On expiration of the license option periods arising after successful completion of the WORK PLAN; or

a)

c) Upon successful completion of a License Agreement, where upon the articles of this agreement shall form the basis of said License Agreement.

d) Upon any termination or expiration of this Agreement, except for Article J.I. c each RECIPIENT will discontinue its use of the CONFIDENTIAL INFORMATION and MATERIALS received from its PROVIDER and upon direction of the PROVIDER, return or destroy any remaining MATERIALS it received from its PROVIDER.

12.

COSTS: Biolnvent agrees to pay a WORK PLAN FEE to InNexus a non refundable/ non creditable R&D WORK PLAN FEE of $10,500 in order to help cover and offset certain portions of the work as outlined in the WORK PLAN

13.

APPLICABLE LAW: This Agreement is made under, and shall be construed according to the laws of the Province of British Columbia Canada.

14.

RIGHT TO AUDIT: InNexus will have the right; at its own cost, to examine the financial records of Biolnvent, once yearly, in order to verify the receipt of any BloInvent Royalties received in order to calculate the exclusivity fee due InNexus. Such inspection will be herd during normal business hours and with a one month advance notice to Biolnvent.

15.

CONFIDENTIALITY: Each of the Parties acknowledged this agreement is subject to the Confidentiality Agreement and its terms and conditions which was entered into and made effective between the Parties; March 8, 2006 of which a copy is appended herein as exhibit D. Neither Party shall make any public statement about this agreement, except if approved by both Parties. The initial press release set forth in Exhibit E is approved by both parties.

16.

NECESSARY DISCLOSURE: If RECIPIENT is required by law, administrative or judicial order to disclose CONFIDENTIAL INFORMATION of its PROVIDER, RECIPIENT shall give PROVIDER prompt notice of such fact so that PROVIDER may obtain a protective order or other appropriate remedy concerning any such disclosure and/or waive compliance with the non-disclosure provisions of this Agreement. RECIPIENT shall fully cooperate with PROVIDER in connection with PROVIDER'S efforts to obtain any such order or other remedy. If any such order or other remedy does not fully preclude disclosure or PROVIDER waives such compliance, RECIPIENT will make such disclosure only to the extent that such disclosure is legally required.

17.

LEGAL RETENTION Subject to any termination of this agreement and upon request by PROVIDER, RECIPIENT will promptly return to PROVIDER all CONFIDENTIAL INFORMATION received from PROVIDER which is in tangible form, except that RECIPIENT shall have the right to retain one copy of such CONFIDENTIAL INFORMATION in its legal archives for the purpose of determining its legal obligations hereunder.

18.

BINDING EFFECT: This agreement shall be binding upon and inure to the benefit of the respective successors and assigns of the parties thereto.

19.

SEVERABILITY: In the event that any portion of this Agreement not vital to the main purpose of this Agreement shall be held illegal, void or ineffective, the remaining portions thereof shall remain in full force and effect.

20.

ASSIGNABILITY: This Agreement, and any rights or obligations hereunder, shall not be assigned by either party without the written consent of the other party, except that a party may otherwise assign its respective rights and transfer its respective duties to any assignee of all or substantially all of its business (or that portion thereof to which this Agreement relates) or in the event of its merger or consolidation or similar transaction.

121`j

12.

21.

LICENSE OBLIGATIONS This Agreement shall in no way, other than outlined in clause 7, be construed to require either party to offer or take a license or other obligation or right not granted or created herein.

22.

REPRESENTATIONS: Both parties represent that the terms of this Agreement are not inconsistent with any other contractual or legal obligations they may have.

23.

EFFECT OF BREACH: Both parties agree that should this Agreement be breached, money damages may be inadequate to remedy any such breach. As a result, the non-breaching party shall be entitled to seek, and a court of competent jurisdiction may grant specific performance and injunctive or other equitable relief as a remedy of any breach of this Agreement. Such remedy may be in addition to all other remedies, including money damages, available to a non-breaching party at law or in equity.

24.

ENTIRE AGREEMENT This Agreement constitutes the entire agreement of the parties and supersedes any and all prior agreements, written or oral, between INNEXUS and BioInvent relating to the subject matter of this Agreement and may not be amended unless agreed to in writing by both parties. All other agreements, written or oral between the parties prior to this agreement are draft working documents.

21.

EACH OF THE PARTIES has caused this Agreement to be executed in duplicate originals which signature pages may be delivered by facsimile to each other by their duly authorized representative where the effective date of this agreement being given below.

Signed this 26th day of September 2006

Je / s

t

Svein Mathisen

President & CEO

President & CEO

InNexus Biotech ology, Inc.

BioInvent International AB

EXHIBIT A: R&D WORK PLAN

This Work Plan presented herein is prepared as a general outline only at this point and upon mutual agreement between the parties is subject to change, modifications, additions and deletions whose end effect is to demonstrate the goals of this work plan.

Work Plan Goal: to demonstrate to mutual satisfaction of the Parties an enhanced potency or therapeutic effect via the application of Super Antibody Technology with an BioInvent Anti HLA-DR antibody for use as an anti cancer therapeutic.

Enhanced Effect: shall mean x% (to be decided before the implementation of the Work Plan) increase over and above the native BioInvent Antibody in the therapeutic potency or apoptosis of the target cancer cell.

Terms and Protocols of the Work Plan will include but not necessarily be limited to the following:

1.

BioInvent MATERIALS: As defined in Exhibit C but in general to mean an Anti HLA-DR antibody in such sufficient amounts as given below to demonstrate the goals of this work plan.

2.

Biolnvent will provide to InNexus 10mg of each of the Antibody listed above.

3.

Defined work flow and schedule of experiments/assays and defined successful outcomes to include: TBA

Biolnvent shall also provide to InNexus, any data, associated analysis, or protocols required by InNexus to carry our the WORK PLAN including the characterization of the antibodies binding data to its TARGET antigen by protein chemical or immunohistochemical methods, and bioactivity data obtained from relevant in vitro and in vivo experiments.

InNexus shall upon receiving the WORK PLAN Fee conjugate the antibodies using its SuperAntibody Technology and then using appropriate and agreed upon QC assays and other cell based assays agreed upon will compare the said antibodies and their unmodified versions thereof for effects of enhanced potency/activity and or apoptosis. These assays shall include any required assays which demonstrate such and may include but not be limited to comparative Annexin V apoptosis assays, FACS analysis and QC/QA analysis, and all other required and mutually agreed upon experimental work needed to demonstrate effectiveness of the SUPER BIOINVENT ANTIBODY defined herein.

Other required assays that are needed to demonstrate effectiveness of the SUPER BIOINVENT ANTIBODY include but is not restricted to affinity measurements with BIACORE technology, in vivo xenograft models, immunohistochemistry analysis. INNEXUS or BioInvent may perform these activities according to the WORK PLAN.

InNexus shall after the Successful demonstration of SUPER BIOINVENT ANTIBODY against TARGET or Substituted TARGET and after an Exclusive License has been entered into, initiate the development of the BIOINVENT EQUIVALENT ANTIBODY. If a BIOINVENT EQUIVALENT ANTIBODY has not been successfully demonstrated by INNEXUS within four (4) months, Biolnvent will have the right to demonstrate a RECOMBINANT EQUIVALENT of SUPER BIOINVENT ANTIBODY against TARGET or Substituted TARGET and thus be subject to a lower milestone fee as outlined in Exhibit B.

In addition to the WORK PLAN FEE, BioInvent agrees the cost of the supplied antibodies will be provided at no cost to InNexus will freely share with BioInvent experimental design information as well as all results from the experiments carried out in the WORK PLAN throughout the course of the WORK PLAN.

EXHIBIT B

			
	WORK PLAN FEES

	Milestone./Service

Fee

	Time

Line

	WORK PLAN starts up 10mg of antibody against TARGET or

Substituted TARGET.

Any subsequent conjugation during the WORK PLAN min 5 mg

	$10,500

$2,500

	4-6

wks

	Event/Milestone Fees

	 
	 

	Successful demonstration of SUPER BIOINVENT ANTIBODY against

TARGET or Substituted TARGET and Exclusive License entered into

	$25,000

	 

	 
	 
	 

	 
	 
	 

	Successful Demonstration by InNexus of RECOMBINANT EQUIVALENT

of SUPER BIOINVENT ANTIBODY against TARGET or Substituted

TARGET.

	 
	 

	 
	$50,000

	10-

12

wks

	Successful Demonstration by BioInvent of RECOMBINANT

EQUIVALENT of SUPER BIOINVENT ANTIBODY against TARGET or

Substituted TARGET.

	$10,000

	 

	Transfer of manufacturing rights of the RECOMBINANT EQUIVALENT

from InNexus to BioInvent. The fee is defined as a fraction of

BioInvent or subcontractors manufacturing cost and due at the end of

each manufactured batch for batches produced for Preclinical Tests or

Clinical Trials but not Commercial Sale.

	10% of

manufacturing cost

per manufactured

I

batch of non-

commercial

material.

	 

	Approval of INDJ

	$300,000

	TBD

	 
	 
	TBD

	Successful Completion of Phase IIa or Phase IIb for first indication

( in the event of Initiation of a Phase Ha

for any possible non-cancer

second indication/TARGET)

	$500,000

(1,000,000)

	 

	Initiation of Phase III

	$2,500,000

	TBD

	First Commercial sale in any territory

	$4,000,000

	TBD

	total

	$7,380,000

	 

Exclusivity Fee

The exclusivity fee comes into effect upon any commercialization of the BioInvent Super HLA-DR antibody for Cancer applications and is payable to InNexus from BioInvent 30 days from the receipt of any Royalty payments received by Biolnvent from any commercial sales or revenue generated. The Exclusivity Fee is defined as a proportion, i.e., 10%, of Net Royalty Payments, after deduction of Biolnvent third party obligations, received by BioInvent from any third Party or commercialisation partner. However, the Exclusivity Fee cannot exceed 0,75°/o of total revenues received by Biolnvent's commercialisation partner or by BioInvent if commercialised by BioInvent.

			
	Revenue Sales by third party

	Revenue net royalty rate

cap

BioInvent receivable

	InNexus

				
	 
	 
	 
	@10%

	100

	7.50%

	7,5

	750

	1,000,000

	7.50%

	75

	7,5

	10,000,000

	7.50%

	750

	75

	50,000,000

	7.50%

	3,750,000

	375

	100,000,000

	7.50%

	7,500,000

	750

	500,000,000

	7.50%

	37,500,000

	3,750,000

	750,000,000

	7.50%

	56,250,000

	5,625,000

	1,000,000,000

	7.50%

	75,000,000

	7,500,000

Exhibit C

Definition of the BioInvent Antibody covered under this agreement: the n-CoDeR-derived IgG1 antibody (clone B-01) specific for a non-polymorphic epitope on human HLA-DR. The VH/VL-sequence is:

BO1-VH

Nucleotide sequence: GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAG CCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG GTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCC AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACTGCCGTGTATTAC TGTGCGAGAGATGGGCTACTACCCCTTGACTACTGGGGCCAGGGTACACTGGTCACCGTGAGCTCA

Aminoacid sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTF55YAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD NS KNTLYLQM NS LRAE DTAVYYCARDG LLPLDYW GQGTLVTVSS

BO1-VL

Nucleotide sequence: CAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGGA GGCAGCTCCAACATCGGAGGGAATGCTGTAAATTGGTATCAGCAGCTCCCAGGAACGGCCCCCAAACTCCTC ATCTATGAAAATAATAAGCGACCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCC TCCCTGGCCATCAGTGGGCTCCGGTCCGAGGATGAGGCTGATTATTACTGCAGCTCATATGCGGTCAGCAAC AATTTCGAGGTGCTATTCGGCGGAGGAACCAAGCTGACGGTCCTAGGT

Aminoacid sequence: QSVLTQPPSASGTPGQRVTISCSGGSSNIGGNAVNWYQQLPGTAPKLLIYENNKRPSGVPDRFSGSKSGTSASL AI5GLRSEDEADYYCSSYAVSN NFEVLFGGGT

Exhibit D

Confidentiality Agreement between the Parties, entered into and made effective; March 8, 2006.

MUTUAL CONFIDENTIALITY AGREEMENT

This Agreement, effective as of the last date of signature ("Effective Date"), is by and between, Biolnvent International AB a Swedish corporation having a place of business at Solvegatan 41, SE-223 0 Lund, Sweden (hereinafter "Biolnvent") and InNexus Biotechnology Inc having a place of business at Suite 2760, 200 Granville Square Vancouver, B.C, V6C 1S4(hereafter "InNexus");

WHEREAS, the parties wish to discuss a possible business relationship (hereinafter "Purpose") and each party may be required to disclose confidential and proprietary information, intellectual property, technical data, trade secrets or know-how, including but not limited to research, product plans, products, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, marketing, distribution, sales methods and systems, and sales and profit figures (hereafter "Confidential Information") to facilitate the Purpose;

Now, THEREFORE, in consideration for the mutual promises made herein and intending to be found hereby, the parties agree as follows:

 1. The words "Receiving Party" and "Disclosing Party" shall hereinafter refer to BIGINVENT and InNexus in their capacity either as recipient or provider, respectively, of Confidential Information under this Agreement. InNexus and BIOINVENT are both "Parties" to this Agreement, and each is a "Party"

 2, The Disclosing Party may disclose the Confidential Information directly or indirectly, in writing, orally, by drawings, or inspection of documents or other tangible property for the Purpose. All Confidential Information shall be marked "Confidential." Any Confidential Information that is not so marked, or is disclosed orally, must (i) be identified as confidential at the time of disclosure, and (ii) the Disclosing Party must provide the Receiving Party with written confirmation within thirty (30) days after such disclosure,

 3. The parties agree that. for a period of five (5) years from the date of any disclosure made hereunder, they will treat the Confidential Information with. the same reasonable care to avoid disclosure of the Confidential Information to any person, firm or corporation as it treats its own Confidential Information, and Receiving Party shall be liable for failure to exercise such reasonable care. The Receiving Party shall have no obligation, with respect to the Confidential Information which:

(a)

is in the public domain at the lime of disclosure or becomes part of the public domain by publication or otherwise, except through breach of this Agreement by Receiving Party;

(b)

was in possession of the Receiving Party at the time of disclosure by Disclosing Party as evidence through written records;

(c)

comes to the Receiving Party from third parties who are entitled to disclose the Confidential Information and who are not under an obligation to Disclosing Party to maintain its confidentiality;

(d)

is authorized in writing by the Disclosing Party to be disclosed;

(a)

(e) is required by law, administrative or ,judicial order to disclose. However, Receiving Party shall give Disclosing Party prompt notice of such requirement in order to give Disclosing Party an opportunity to obtain a protective order or other appropriate remedy concerning any such disclosure and/or waive compliance with the non-disclosure provisions of this Agreement. Receiving Party shall. fully cooperate with Disclosing Party in connection with Disclosing Party's efforts to obtain any such order or other remedy, If any such order or other remedy does not fully preclude disclosure or Disclosing Party waives such compliance, Receiving Party will make such disclosure only to the extent that such disclosure is legally required,

The fact that general information may be in, or become part of the public domain, in and of itself, does not exclude any specific information from the obligations of this Agreement.

4.

 Acceptance of the Confidential Information by the Receiving Party shall give the Receiving Party the right to use the Confidential Information solely for the Purpose in accordance with this Agreement.

5.

 Receiving Party's internal dissemination of Disclosing Party's Information shall be limited to those employees whose duties justify the need to know such information, Receiving Party will make all necessary efforts to require their officers, directors, employees, agents, who have been given access to and who shall receive disclosures of the Information to maintain the strictest secrecy under the terms and conditions of this Agreement provided hereunder.

6.

 The Parties acknowledges that the restrictions contained in this Agreement are, in view of line nature of the Confidential Information, reasonable and necessary to protect the legitimate proprietary interests of the Parties and any breach of any provision of this Agreement by a Party will result in substantial and irreparable harm to the other Party.

7,

 Upon request of the Disclosing Party, Receiving Party will promptly retrun to Disclosing Party all tangible forms of Confidential Information received from Disclosing Party, except that Receiving Party shell have the right to retain one copy of such Confidential Information in its files for the sole purpose of determining its legal obligations hereunder.

8,

 Neither Party shall assign any of its rights or obligations under this Agreement, by operation of' law or otherwise, including merger, consolidation, or other business reorganization, stock transfer or otherwise, Any attempt to do so shall be void. Subject to the foregoing, all terms and provisions of this Agreement shall be binding upon and inure to the benefit of, and be enforceable by the respective successors and assigns of the parties hereto,

 9. If any provision of this Agreement or the application thereof to any person or circumstance is held void, illegal, invalid, ineffective or unenforceable in any jurisdiction, the remainder of this Agreement and the application of such provision to such person or circumstance in any other jurisdiction or to other persons or circumstances in any jurisdiction, shall not be affected thereby, and to this extent, the provisions of this Agreement shall be severable. It is the Parties' intention that any such provision shall be reformed and construed by the court to provide the protected party the maximum protection permissible by law.

10. No patent right or license is granted to either Party by this Agreement by the other Party except the right to use Confidential Information solely for the purpose set forth above, and that the disclosure of Confidential Information does not result in any obligation by the Disclosing Party to grant to the Receiving Party any right, title or interest in, or any license under any patent, or in any of such Confidential Information by implication, estoppel or otherwise, other than that specifically provided heroin.

II, Neither Party shall be obligated to disclose or to receive Confidential Information. Notwithstanding anything in this Agreement to the contrary, neither Party shall be obliged to enter into any further agreement or understanding relating to the Confidential Information or arising out of the Purpose.

12. Both Parties represent that the terms of this Agreement are not inconsistent with any other contractual or legal obligations they may have. Each party acknowledges that the Confidential Information is provided on an "AS IS" basis. In no event shall the Disclosing Party be liable to (he Receiving Party for any direct, indirect, special, or consequential damages in connection with or arising out of the performance or use of any portion of the Confidential information, including without limitation or representation or warranty as to completeness, accuracy, safety or fitness for a. particular purpose.

13. This Agreement shall be executed, carried out in good faith and governed, interpreted and enforced according to the laws of the Province of British Columbia. BIO1NVENT and InNexus hereby submit to the jurisdiction of a court located in the Province of British Columbia and waive any objections to such jurisdiction to any controversies arising out of this Agreement,

14. This Agreement constitutes the entire Agreement between InNexus and BIOINVE.NT pertaining to the confidentiality and use of Confidential Information and supercedes any prior or contemporaneous agreements, representations, and understandings of the parties with respect thereto, No supplement, modification or amendment of this Agreement shall be binding upon the parties except as set forth in a written agreement executed by the parties.

IN WITNESS WHEREOF, the parties have signed or caused this Agreement to be executed as of the date indicated on the following page.

BIOINVENT

Name: ROLAND CARLSSON

Title: VP RESEARCH

Date:  March 8, 2006

I

Exhibit Exhibit E.

September 21, 2006

PRESS RELEASE

InNexus Enters R&D Agreement Targeting Cancer with BioInvent of Sweden

Vancouver, British Columbia - InNexus Biotechnology Inc. (TSX VENTURE: IXS) (OTCBB: IXSBF), an innovative antibody-driven drug development company, today announced that it has entered into an R&D agreement with BioInvent International AB, a publicly-traded biotech, for the provision of InNexus' SuperAntibodyTt' Technology with a BioInvent therapeutic antibody targeting cancer. Under the agreement the Parties will perform collaborative R&D for a single target. The agreement also contains terms for future drug development including commercialization. Financial terms of the transaction were not disclosed.

Commenting on the announcement, Jeff Morhet, President & CEO of InNexus said, "We are delighted to be entering into this relationship with BioInvent as our extensive antibody enhancement experience underpins all of our technologies. This enables us to offer state of the art support to pharmaceutical and drug development companies as we seek to increase antibody potency, an achievement already demonstrated with other multiple fully human and humanized antibodies. The impact of such a demonstration is to not only produce a more effective drug candidate but to also use less amounts of drug, key to the drug's cost of goods and profit."

Morhet continued, "This agreement also demonstrates InNexus' ability and commitment to develop SuperAntibocly Technology into commercial product opportunities internally and for our partners."

About InNexus

InNexus is an innovative antibody-driven drug development company that has developed two technology platforms, SuperAntibody' and TransMAbsTM, which improve the potency of existing antibody products while opening new markets and disease applications. Both platforms utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in Scottsdale, Ariz., on the campus of The Mayo Clinic and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.innexusbiotech..com.

About Biolnvent

BioInvent International AB, listed on the 0 list of the Stockholm Stock Exchange (SAX:BINV), is a research-based pharmaceutical company that focuses on development of antibody-based drugs. The Company is running innovative drug projects within the areas of thrombosis, oncology, atherosclerosis, ophthalmic diseases and HIV. The Company, which currently has 99 employees, is located at Ideon in Lund, Sweden.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the company's proposed activities.

InNexus Biotechnology Inc.

Jeff Morhet, President & CEO 1-888-271-0788

E-mail: jmorhet@innexusbiotech.com

The TSX Venture Exchange has neither approved nor disapproved of the information contained herein.

Endnotes

Page 1

Page 2

Page 3

Page 4

Page 5

Page 6

Page 7

Page 8

Page 9

Page 10

Page 11

7 )

Page 12

Company C DA 2004

TOTAL P.05

By:

Name :Garth likes

Title : VP Business Development Date: March 31, 2006

17)MTA & Work Plan

CONFIDENTIAL

INNEXUS EVOGENIX MATERIAL TRANSFER AGREEMENT

This MATERIAL TRANSFER AGREEMENT (Agreement), is made effective as of August 1st, 2005 (Effective Date) and is entered into by and between InNexus Biotechnology Inc., a Canadian corporation having an address at 14th Floor, Commerce Place, 400 Burrard Street, Vancouver, BC, V6C 3G2, Canada (InNexus) and EvoGenix Ltd an Australian Corporation having an address at Level 2, 37 Bligh Street, Sydney NSW 2000 Australia,  (EvoGenix) and subsequently both herein shall be referred to collectively as the “Parties”.

WHEREAS, each of the Parties is interested in evaluating the use of its respective technologies for the potential development of therapeutic antibodies and/or diagnostics tests in the general area of infectious diseases or other such areas as may be designated and in connection therewith the parties desire for EvoGenix to transfer to InNexus certain proprietary materials of EvoGenix, (the EvoGenix Materials) and for InNexus to transfer to EvoGenix certain proprietary materials (the Combined Materials, incorporating both InNexus Materials and EvoGenix Materials) solely for the purpose of facilitating such evaluation; and

WHEREAS, upon a successful completion of the evaluation both parties may agree to enter into a further collaborative and licensing agreement, and 

WHEREAS, in order to facilitate such evaluation, the Parties desire for InNexus to perform certain conjugations of the EvoGenix Materials (as defined below) using a quantity of EvoGenix Materials as provided by EvoGenix hereunder and other required assessments (the InNexus Activities) and for EvoGenix to perform further required assessments (the EvoGenix Activities) of the Combined Materials as supplied to it; and

NOW, therefore, the Parties agree as follows:

1.

Transfer of EvoGenix Materials.  EvoGenix agrees to deliver a certain quantity of the EvoGenix Materials (as defined below) to InNexus in the manner specified in Exhibit D for the sole purpose of allowing InNexus to carry out work with the EvoGenix Materials (the “InNexus Activities”), such work to be performed by InNexus as set forth in Exhibit C.  

2.

Transfer of Combined Materials.  Following performance of the InNexus Activities described in 1 and Exhibit C, InNexus will transfer materials created  (the Combined Materials) to EvoGenix in the manner specified in Exhibit D for the purpose of evaluation of the Combined Materials as set forth in Exhibit C.

3.

The transfer of the EvoGenix Materials or InNexus Materials or Combined Materials by one Party to another hereunder constitutes the grant of a non-exclusive license to the receiving Party to use the transferred Materials during the term of this Agreement solely to perform the Activities.  This Agreement does not in any way restrict the transferring Party’s right to distribute any of its own Materials (but not the Combined Materials) to other commercial or non-commercial entities.  Neither Party shall have any obligation to grant a further license to the other Party, and may grant exclusive or non-exclusive licenses to third parties who may be investigating any other uses of its own Materials (but not the Combined Materials).

4.

Definitions.

a.

For purposes of this Agreement, “InNexus Materials” shall mean the proprietary materials described in Exhibit A, as well as any derivatives, progeny, forms or improvements developed there from; provided, however, the InNexus Materials shall not include any EvoGenix Materials or the Combined Materials.

b.

For purposes of this Agreement, “EvoGenix Materials” shall mean the proprietary materials of EvoGenix as described in Exhibit B, as well as any derivatives, progeny, forms, or improvements developed there from; provided, however, the EvoGenix Materials shall not include any InNexus Materials or the Combined Materials.

c.

For purposes of this Agreement “Combined Materials” shall mean that material created which is the sum of, or the combination of the EvoGenix Materials and the InNexus Materials as developed and defined within the Activities as defined by the work plan attached as Exhibit C.

d.

For the purposes of this Agreement “Materials” shall mean the EvoGenix Materials, the InNexus Materials and the Combined Materials.

e.

For the purposes of this Agreement “Intellectual Property Rights” shall mean statutory and other proprietary rights in respect of copyright and neighbouring rights, all rights in relation to inventions, patents, plant varieties, registered and unregistered trade marks, registered and unregistered designs, circuit layouts and rights to require information be kept confidential, but does not include moral rights that are not transferable.

f.

For purposes of this Agreement, the “Activities” shall mean the activities described in the work plan set out in Exhibit C, incorporating the InNexus Activities and the EvoGenix Activities.

5.

Limitation of Use.  InNexus agrees to use the EvoGenix Materials and Combined Materials only for the performance of the Activities and not for any other use or purpose without the prior express written consent of the other Party.  EvoGenix agrees to use the InNexus Materials and the Combined Materials only for the performance of the Activities and not for any other use or purpose without the prior express written consent of the other Party.  Such use will occur solely in the laboratories of a Party under suitable containment conditions, and such Party shall only grant access to the other Party’s Materials to those of its employees or consultants who require such access for the performance of the Activities, who have been made aware of the confidentiality obligations contained in this Agreement and who are bound by substantially equivalent obligations of confidentiality.

6.

Results.  Unless otherwise agreed to in writing by the other Party, neither Party shall publish the results, data or information regarding any evaluation of the Combined Materials (collectively, the “Results”) nor disclose the Results to third parties.  

7.

Records.  During the term of this Agreement and thereafter until the return or destruction of the other Party’s Materials, each Party will prepare and maintain complete and accurate written records of all uses made of such Materials, and, upon the other Party’s request, copies of such records will be furnished to the other Party; provided, however, that the other Party will treat such records as confidential information of the providing Party subject to the terms and conditions of the Confidential Information Agreement (as defined below).

8.

Confidentiality.  All information that either Party receives from the other Party, as well as all Results, shall be considered “Confidential Information”  as given and as previously defined under that certain Confidential Non-Disclosure Agreement (Two-Way) between the Parties, previously signed (the “Confidential Information Agreement”).  Neither the Confidential Information Agreement nor any provision of this Agreement shall be deemed to prevent either Party from using or disclosing for any purpose information relating solely to such Party’s Materials.

9.

Ownership and Control of InNexus Materials.  InNexus shall have title to all InNexus Materials and all Intellectual Property Rights in them and, except as set forth in Section 1 and Section 11, nothing in this Agreement grants EvoGenix any rights under any Intellectual Property Rights of InNexus.  During the term of the Agreement, EvoGenix shall retain control over any InNexus Materials provided to EvoGenix hereunder.  EvoGenix shall at no time transfer any InNexus Materials to any third party without InNexus’ prior written consent.  

10.

Ownership and Control of EvoGenix Materials.  EvoGenix shall have title to all EvoGenix Materials and all Intellectual Property Rights in them and, except as set forth in Section 1 and Section 11, nothing in this Agreement grants InNexus any rights under any Intellectual Property Rights of EvoGenix.  During the term of the Agreement, InNexus shall retain control over any EvoGenix Materials provided to InNexus hereunder.  InNexus shall at no time transfer any EvoGenix Materials to any third party without EvoGenix’ prior written consent.  

11.

Ownership and Control of Combined Materials.  Subject to this article and article 13 herein each of the Parties shall own jointly any Intellectual Property Rights relating to the Combined Materials or the Results arising from use of the Combined Materials.  The Parties hereby agree that the Combined Materials are created solely for the purpose of performing the Activities, and that no patent application will be filed in respect of the Combined Materials or incorporating the Results arising from use of the Combined Materials unless otherwise agreed in writing between the Parties.  Neither party may commercially exploit any Combined Materials or any Intellectual Property Right relating to the Combined Materials or the Results arising from use of the Combined Materials, other than pursuant to a further written agreement between the Parties.

12.

Destruction of Materials.  Promptly upon the earlier of (i) completion of the Activities or (ii) termination or expiration of this Agreement, unless the Parties agree otherwise in writing, each Party shall, at the election of the other Party, return to the other Party or destroy all the other Party’s Materials and the Combined Materials then in its possession. 

13.

Intellectual Property Rights.  Unless otherwise provided herein, ownership of all Intellectual Property Rights created, and any technique, process, apparatus, material, product, data, formula, software, design, trade secret, improvement, know-how or invention, whether patentable or not, made, in performing the Activities (“Evaluation Inventions”) will follow the United States laws of inventorship. 

(a) In the event that EvoGenix develops an Evaluation Invention which relates exclusively to the InNexus Materials, and not the EvoGenix Materials, EvoGenix shall promptly provide written notice to InNexus of such Evaluation Invention and will, upon the request of InNexus, assign such Evaluation Invention to InNexus for no additional consideration.

(b) In the event InNexus develops an Evaluation Invention which relates exclusively to the EvoGenix Materials, and not the InNexus Materials, InNexus shall promptly provide written notice to EvoGenix of such Evaluation Invention and will, upon the request of EvoGenix, assign such Evaluation Invention to EvoGenix for no additional consideration.

(c)  Ownership in Evaluation Inventions and Results obtained relating to the Combined Materials will vest equally in the Parties as outlined in Clause 11.

(d) All notices described in this Section 13 shall provide a detailed description of the relevant Evaluation Invention.

14.

Management of the Activities.  Each Party shall nominate a Project Leader, who shall be responsible for transfer of Materials, ensuring timely performance of that Party’s Activities, reporting to the other Party on Results and Inventions, and providing reports to the management of both Parties on the progress of the Activities.

15.

Review of Results.    At appropriate intervals during the course of the Activities, and at the conclusion of the Activities, the Parties will meet to review the Results and to determine any further actions to be undertaken which may include but are not limited to, a further or modified experimental program, negotiation of a license or other relationship, patenting of the Results, or agreement on the future use of the Results by either or both parties.  

16.

No Warranty.  The EvoGenix Materials and the InNexus Materials are for the sole purpose of facilitating the Activities.  THE EVOGENIX MATERIALS AND THE INNEXUS MATERIALS ARE BEING SUPPLIED “AS IS”, WITH NO WARRANTIES, EXPRESS OR IMPLIED, AND EVOGENIX AND INNEXUS EXPRESSLY DISCLAIM ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT.

17.

No materials in this evaluation MAY BE USED IN HUMAN SUBJECTS.  The Combined Materials will only be used by the Parties for the Activities under suitable containment conditions and for purposes of exploring the possibility of entering into a further collaborative research agreement. 

18.

Care in Use of the Materials.  Each Party acknowledges the Materials are experimental in nature and may have unknown characteristics and therefore agrees to use prudence and reasonable care in the use, handling, storage, transportation, disposition, and containment of the Materials.  Each Party agrees to maintain the Materials under suitable containment conditions in compliance with all applicable national, state and local laws, regulations, rules and ordinances. 

19.

Hold Harmless.  Each Party (the “Indemnifying Party”) shall indemnify, defend and hold harmless the other Party (the “Indemnified Party”) and its officers, agents and employees from any liability, loss or damage they may suffer as a result of claims, demands, costs or judgments against the Indemnified Party arising from or in connection with the InNexus Activities or other activities conducted by the Indemnifying Party under this Agreement, except insofar as such liability arises out of the Indemnified Party’s negligence or intentional misconduct.

20.

Compliance with Laws.  Each of the Parties shall use the EvoGenix and InNexus Materials and the Combined Materials in compliance with all applicable laws and regulations of the Province of British Columbia, Canada,, or equivalent laws and regulations that apply in any other State, Province or Territory, where the Activities may be undertaken.

21.

No Conflict.  Each of EvoGenix and InNexus represent that this Agreement does not, and during the term of this Agreement will not, conflict with any other right or obligation provided under any other agreement or obligation that such Party has with any third party.

22.

Term of Agreement.  This Agreement shall remain in effect for 12 (twelve) months from the Effective Date.  Either Party may terminate this Agreement for any reason immediately upon written notice to the other, which notice shall be effective on receipt.  Upon termination or expiration of this Agreement for any reason, the following provisions shall survive: Sections 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 17, 19 and 20.

23.

General.  This Agreement contains the entire agreement between both Parties with respect to the subject matter of this Agreement and supersedes any previous understandings, commitments or agreements, oral or written, regarding such subject matter.  This Agreement shall be governed by and construed under the laws of the Province of British Columbia, Canada, without regard to its conflict of laws principles.  The Parties hereby submit to the exclusive jurisdiction of the courts of British Columbia in all matters concerning this Agreement.  This Agreement may be modified only by a subsequent written agreement signed by both Parties.  If any provision of this Agreement is held to be unenforceable, the remaining provisions shall continue unaffected.

24.

Independent Contractors; Use of Party’s Name.  The relationship of the Parties hereto shall be that of independent contractors.  The Parties hereto shall not be deemed to be agents, employer-employee, partners or joint ventures of the other for any purpose as a result of this Agreement or of the transactions contemplated thereby.  Neither Party shall use the name of the other Party for promotional purposes without the prior written consent of the Party whose name is proposed to be used.  No news release, publicity or other public announcement, either written or oral, regarding the terms and/or existence of this Agreement, or performance hereunder, shall be made by either Party without the prior written approval of the other Party.

25.

Assignment.  Neither Party may assign this Agreement to any third party without the written consent of the other Party, which consent shall not be unreasonably withheld; provided each Party may assign this Agreement, without the other Party’s consent, to an affiliate company of the Party, or to an entity that acquires all or substantially all of the business or assets of the assigning Party to which this Agreement pertains, whether by merger, reorganization, acquisition, sale or otherwise.

26.

No Waiver:  No delay or indulgence by a Party in enforcing this Agreement will prejudice or restrict the rights of that Party, nor will a waiver of those rights operate as a waiver of a subsequent breach.

27.

Severability:  If a provision of this Agreement offends any applicable law, or is unlawful, invalid or unenforceable, then where the provision can be read down so as to be valid and enforceable it must be read down to that extent, or otherwise will be deigned to be severed from the other provisions.

IN WITNESS THEREOF, each of the Parties has caused this Agreement to be executed by a duly authorized representative on the dates entered herein below, and said representatives hereby warrant that they have been duly authorized to sign this Agreement on behalf of their respective Parties.  

		
	EVOGENIX, LTD.

Signature:

 

“Merilyn Sleigh”

Date

:

_________________

:

October 28, 2005

Name (print): 

Merilyn Sleigh PhD

Title:

CEO and Managing Director­­­­

______

	INNEXUS BIOTECHNOLOGY, INC.

Signature:

Date:  13 October 2005

Name:  Alton C. Morgan Ph. D.

Title:  

President & CEO

1

InNexus Biotechnology, Inc. MTA (8-4-05)

CONFIDENTIAL

EXHIBIT A

Description of InNexus Materials - 

All material related to Super Antibody Technology, including but not limited to autophillic conjugated peptides and related conjugated peptides as covered under  all InNexus patents filed or applied for, or  any improvements continuances thereof as listed herein plus any other InNexus material which is to be included as defined within Exhibit C herein.

EXHIBIT B

Description of EvoGenix Materials – All material related to EvoGenix Antibody Technology, including but not limited to forms of antibodies directed against Respiratory Syncytial Virus (RSV)  and related as covered under all EvoGenix patents filed or applied for, or any improvements or continuances thereof as listed herein plus any other EvoGenix Material which is to be included as defined within Exhibit C herein.

EXHIBIT C

Preliminary Description of the Activities - ( to be further discussed as required)

EvoGenix will at its own expense supply InNexus for the InNexus Activities: 

§

Up to ten (10) mg of a full length antibody and a Fab fragment of one or more  antibodies directed against Respiratory syncytial virus (RSV). Further EvoGenix will supply  all relevant information on the antibody or Fab to include where known or relevant:

§

Description of antibody 

§

Species

§

Ig class

§

Humanized or chimeric etc

§

Monoclonal or polyclonal

InNexus will at its own expense:

§

Conjugate the RSV FAb with its material, i.e. the autophillic T15 peptide at the tryptophan binding site or the nucleotide binding site (as appropriate).  The materials produced as a result of this conjugation using any antibodies in whatever format supplied as EvoGenix Materials, will be the Combined Materials.

§

Assay the newly created Super Antibody form of the EvoGenix antibody (the Combined Materials) for proof of conjugation and other general quality controls using its standard QC assays (including efficiency of conjugation and contamination by aggregated protein)

§

InNexus will transfer sufficient amounts (as determined by the Project Leaders) of the Combined Materials in sufficiently purified form to EvoGenix, so that it may carry out the EvoGenix Activities

EvoGenix will at its own expense:

§

Assay the Combined Materials for virus binding and antiviral activity which may involve certain ELISA assays, cell based assays, and or other such to be determined assays which would demonstrate enhanced potency, cross linking or potential use as an infectious disease therapeutic or diagnostic product. A positive result is defined as a significant increase in antigen binding and a significant increase in neutralization potency.

It is recognized that during the term of the Agreement, a number of different versions of the above Super Antibody (Combined materials) may be created.  Each party will endeavor to carry out its obligations under this Agreement to perform the Activities within a reasonable time frame.

EXHIBIT D

Transfer of Materials:  All Materials to be transferred by one Party to the other under this Agreement shall be transferred as follows:

Packaging

ice or dry ice

Method of Transport

Fedex or equivalent

1

InNexus Biotechnology, Inc. MTA (8-4-05)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]